Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465437 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2 study, sponsored by Corbus Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT02465437 is a Phase 2 study that was terminated before completion, run by Corbus Pharmaceuticals. The registered enrollment target is 42 participants.
The verdict
NCT02465437, a Phase 2 study, was terminated before completion, sponsored by Corbus Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in adult subjects with diffuse cutaneous systemic sclerosis.
Interventions
- DRUG Placebo
- DRUG JBT-101
- DRUG Part B Open-Label Extension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-08 |
| Est. Completion | 2020-12-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02465437
The ClinicalTrials.gov registry entry for NCT02465437 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corbus Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02465437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02465437 about?
NCT02465437 is a clinical study titled "Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in adult subjects with diffuse cutaneous systemic sclerosis.
What is the current status of trial NCT02465437?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2015-08. Estimated completion is 2020-12-11.
What interventions are being tested in trial NCT02465437?
The interventions under investigation include: Placebo (DRUG), JBT-101 (DRUG), Part B Open-Label Extension (DRUG).
Who is sponsoring clinical trial NCT02465437?
This trial is sponsored by Corbus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.